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Respiratory infections, the most common
cause of acute infectious disease in U.S. adults
(1), are also the leading cause of outpatient
illness and a major cause (25% to 30%) of
infectious disease hospitalization in U.S.
military personnel (2,3). Because of crowded
living conditions, stressful working environ-
ment, and exposure to respiratory pathogens in
disease-endemic areas, military trainees and
newly mobilized troops are at particularly high
risk for respiratory disease epidemics (2, 4-6).
For example, before vaccines were used, more
than 80% of military trainees had respiratory
infections, and as many as 20% were hospitalized
during the 2 months of recruit training (7).
Although respiratory disease control is im-
proved, epidemics continue to occur, and
respiratory disease in military trainees contin-
ues to exceed that in U.S. civilian adults
(Figure 1). The recent loss of adenovirus vaccine
(types 4 and 7) production, changes in the
susceptibility of pathogens to antimicrobial
drugs, and emerging respiratory pathogens
threaten to increase the military populations
vulnerability to respiratory diseases.
We review the changing epidemiology and
control of six major respiratory disease
pathogens of special concern to the military.
Adenoviruses
Respiratory disease agents discovered in
adenoidal tissue in U.S. soldiers in the 1950s
were associated with rhinitis, pharyngitis,
conjunctivitis, pneumonitis, and atypical pneu-
monia and were subsequently designated as
adenoviruses (14). In 1958, adenoviruses caused
hospitalization of an estimated 10% of military
recruits (15). Adenoviral disease was highest
during winter, accounting for 90% of all recruits
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Figure 1. Hospitalization rates for acute respiratory
disease per 10,000 persons, 1991 to 1994: U.S. army
recruits vs. young adults in U.S. nonfederal hospitals.
U.S. army recruit estimates are converted from
percentage febrile acute respiratory disease rates per
100 trainee-week figures (8). On average, recruits
were 19 years old. U.S. national nonfederal estimates
were taken from first-listed diagnoses with the
International Classification of Diseases codes 460 to
466 (9) among persons of ages 15 to 44 years (10-13).380 Emerging Infectious Diseases Vol. 5, No. 3, MayJune 1999
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Figure 2. Department of Defense medical treatment
facilities and recruit training camps participating in
surveillance for emerging respiratory disease patho-
gens: invasive Streptococcus pneumoniae (typing and
antibiotic sensitivity studies); Streptococcus pyogenes
(typing and antibiotic sensitivity studies); and
adenovirus (typing studies).
hospitalized with pneumonia (16,17) and 72% of
all respiratory disease (17). Military recruits had
a greater chance of acquiring adenoviral
infections than similar civilian populations, with
most infections occurring during the first
3 weeks of military training (16,18,19). Of the 47
adenoviral serotypes, types 4 and 7 accounted for
most military respiratory disease epidemics. A
1965 study of a typical epidemic at Fort Dix, New
Jersey, established the need for vaccines (20).
In 1971, the Department of Defense (DoD)
began routine use of live, enteric-coated types 4
and 7 vaccines, which have remained very
effective (6). Vaccine development for other
serotypes that cause only infrequent epidemics
was begun, but no vaccine became licensed.
Recently, the sole manufacturer of the adenovi-
rus type 4 and type 7 vaccines ceased production,
so neither vaccine is available. The unavailabil-
ity of adenovirus vaccines threatens a sharp
increase in numbers of acute respiratory disease
epidemics in the military, especially among
recruits (6). Recently, two recruit centers where
the vaccines were not available had large acute
respiratory disease epidemics (21,22).
The ecologic and pathologic features of
adenoviruses in military populations are poorly
understood (23,24). Most available surveillance
data are more than 20 years old (7,20). To better
understand the distribution of adenovirus
serotypes, risk for infection, and agent dynamics
following vaccine loss, triservice adenovirus
surveillance has been established at five military
training centers (Figure 2) (25). Early data
indicate that types 4 and 7 vaccines remain
effective, but nonvaccine serotypes are prevalent
and should be considered in new vaccine
development strategies. More than 55% of 3,212
throat cultures from symptomatic trainees from
October 1996 to May 1998 yielded adenoviruses.
Most prevalent were types 4 (46%), 7 (32%),
3 (13%), and 21 (5%). Among trainees with acute
respiratory infection symptoms, nonvaccinated
personnel were at greater risk of having a
culture positive for adenovirus types 4 and 7
(odds ratio = 41.2; 95% confidence interval = 18.7
to 113.2) than vaccinated personnel. Capability
to isolate and identify adenoviruses has
improved, but simple rapid molecular diagnostic
techniques have not yet been developed.
Influenza
Since an annual influenza vaccine policy was
adopted for active-duty personnel in the 1950s,
massive influenza epidemics have largely ended.
However, the potential for illness and death due
to new viral strains remains. During the last
3 months of 1918, an influenza A pandemic
affected 106,897 (18.8%) of 569,470 navy
personnel, with an estimated case-fatality rate of
4.5%. The case-fatality rate was particularly
high among military trainees, especially those
who had pneumonia. For example, during a
30-day period beginning in September 1918,
9,623 (21.5%) of 44,605 navy trainees (Illinois)
had influenza, and 924 died; the case-fatality
rate was highest (48%) among those with
pneumonia (26). At autopsy, streptococcal organ-
isms were often associated with pneumonia, which
suggests that pathogens in the training camps may
have exacerbated the influenza illnesses and
deaths during this pandemic.
Even with annual use of influenza vaccine,
laboratory-based surveillance is critical. During
February 1996, a U.S. navy ship with a 600-
person crew had an estimated 42% influenza A
attack rate, although more than 95% of the crew
had received the annual influenza vaccine
(K. Earhart, pers. comm.). The annual vaccine
for that winter (A/Johannesburg/33/94-like
[H3N2] and A/Texas/36/91-like [H1N1]) did not
protect against the A/Wuhan/359/95 [H3N2]
strain that infected the crew.
The recent outbreak of H5N1 influenza A in
Hong Kong prompted a review of capability to
detect new influenza strains (27); only the air
force was conducting a laboratory-based surveil-381 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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Figure 3. Military sites in the United States
participating in Department of Defense influenza
surveillance. The focus of surveillance at etiology-
based sites is to determine the viral causes of
influenzalike illnesses; the focus of population-based
sites is to closely monitor for influenzalike illness
epidemics.
lance program (28). Since the Hong Kong
outbreak, a cooperative global influenza surveil-
lance network has been formed. Worldwide,
more than 20 medical treatment facilities and
laboratories from all services are collecting
influenza isolates for typing (Figure 3) (29).
Additionally, in the United States, military
training sites at high risk for influenza are
monitored so that epidemics might be quickly
detected. This early warning system allows
public health officials to modify vaccine antigens,
use antiviral drugs, and take other measures to
reduce illness.
Streptococcus pneumoniae
Before penicillin was introduced, complica-
tions of S. pneumoniae infections were frequent
and often fatal. Large epidemics of pneumonia
occurred in crowded military populations,
particularly after influenza outbreaks, espe-
cially during winter. In 1918, a 1-month
epidemic of S. pneumoniae in a military camp in
Illinois resulted in 2,349 hospital admissions
with a 50% death rate (30). From the 1960s to the
1980s, military epidemics of pneumococcal
disease were very rare. However, in recent years,
military pneumococcal epidemics have occurred
in southern California (31), in North Carolina
(32), and among a ships crew in the
Mediterranean Sea (4).
S. pneumoniae infections have various
clinical features, including pneumonia, meningi-
tis, empyema, bacteremia, conjunctivitis, sinusi-
tis, arthritis, and otitis media. Since the
introduction of penicillin, epidemics of respira-
tory disease caused by S. pneumoniae are much
less frequent but remain a threat. To counter
outbreaks, the military has used mass prophy-
laxis with benzathine penicillin G (1.2 million
units) intramuscularly (31). However, the
efficacy of this intervention and its impact on
antibiotic resistance have not been fully
evaluated (33). In 1991, the Armed Forces
Epidemiological Board recommended pneumo-
coccal vaccine (23-valent polysaccharide) for
populations at high risk for S. pneumoniae
infection. However, because of the cost and
uncertainty about efficacy in healthy young
adults, the vaccine is given only to trainees at
one marine corps installation.
During the last 20 years, penicillin-resistant
S. pneumoniae (intermediate and highly
resistant strains), as well as multidrug-resistant
strains, have been reported with increasing
frequency throughout the world. Recently,
investigators from Korea reported that 70% of
131 clinical civilian pneumococcal isolates were
penicillin-resistant (34). On the basis of limited
surveillance data, the public health threat of
penicillin-resistant  S. pneumoniae to U.S.
military personnel and their dependents is
increasing (35). Walter Reed Army Medical
Center, Washington, D.C., reported an increase
in the percentage of penicillin-resistant
S. pneumoniae isolates from 0% in 1990 to 36.2%
in 1994 (36).
In winter 1989-90, an outbreak among
marine trainees at Camp Pendleton, California,
resulted in 128 reported cases of pneumonia, one
of the largest epidemics since the development of
antibiotics. The epidemic triggered mass
prophylaxis with benzathine penicillin G and
administration of pneumococcal vaccine (31).
Soon after, other smaller epidemics of pneumo-
coccal pneumonia occurred among U.S. army
rangers (32) and among the crews of two navy
ships in Italian waters (4). As we write (March
1999), another pneumococcal pneumonia out-
break among army trainees is under epidemio-
logic investigation. These recent pneumococcal
epidemics may be evidence of a changing
epidemiologic threat. Pneumococcal pneumonia,
which was checked when antibiotics became
available in the 1950s, seems to have reemerged.
Increasing antibiotic resistance and epidem-
ics prompted surveillance for invasive382 Emerging Infectious Diseases Vol. 5, No. 3, MayJune 1999
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S. pneumoniae disease (Figure 2). Early data
from patients hospitalized in military hospitals
in the United States are consistent with data
from civilian U.S. populations. On average, 35%
of isolates have full or partial resistance to
penicillin (35,37). Thus far, nearly all invasive
isolates are of types included in the 23-valent
vaccine. A cost-effectiveness analysis projected
that using this vaccine among new navy and
marine corps personnel would result in a lifetime
savings of approximately $9 million (38).
Streptococcus pyogenes
U.S. military populations have frequently
had large S. pyogenescaused epidemics of
pharyngitis and acute rheumatic fever, accom-
panied by other concomitant diseases, such as
pneumonia, sepsis, polymyositis, necrotizing
fasciitis, scarlet fever, and glomerulonephritis
(5,39). Historically, because of cramped living
conditions, military recruits have been at high
risk for streptococcal disease (2,5,39,40). Illness
was especially high in World War II, with the
navy reporting approximately one million
streptococcal infections and more than 21,000
cases of acute rheumatic fever (5,41).
In 1948, Massell et al. (42) reported that the
treatment of acute pharyngitis infection with
oral penicillin prevented acute rheumatic fever.
Further studies confirmed the effectiveness of a
single intramuscular injection of benzathine
penicillin G in preventing a broad range of acute
and chronic sequelae of streptococcal infections
(5,40,43). These early successes led to mass
antimicrobial prophylaxis with benzathine
penicillin G in training populations at high risk
to interrupt and prevent outbreaks of acute
disease and their sequelae (44). This control
strategy was generally very effective. However,
a 1989 epidemic of S. pyogenes pharyngitis
among marine corps trainees demonstrated that
benzathine penicillin G prophylaxis for
nonpenicillin-allergic trainees alone might not
protect against epidemics in closely contained
populations, especially those with longer
training periods, as unprotected penicillin-
allergic recruits may serve as S. pyogenes
reservoirs. This finding led to the navys
adoption of oral erythromycin as prophylactic
therapy for penicillin-allergic recruits (39,45).
Another study has shown that 500 mg of
azithromycin taken orally each week is, by
serologic evidence, an effective prophylactic
intervention against S. pyogenes (33).
Since the development of antibiotic prophy-
laxis, civilian and military epidemics of
S. pyogenes disease have declined and then
reemerged  (39,46,47). Epidemics of acute
rheumatic fever have occurred throughout the
United States (46-48). In addition, an estimated
10,000 cases of severe S. pyogenes disease, such
as necrotizing fasciitis and streptococcal toxic
shock, occur nationwide each year (49-52).
Increases in invasive streptococcal disease
among some U.S. populations have been
attributed to changes in the prevalence of
virulent strains of S. pyogenes(53).
Although antibiotic prophylaxis remains
effective,  S. pyogenes persists as a leading cause
of bacterial respiratory illness among military
personnel (5,39,47,48,54). Risk factors associ-
ated with S. pyogenes infection include recent
entry to the military, crowding, lack of
prophylaxis, close contact with an S. pyogenes
carrier, and close contact with a trainee who has
not received antibiotic prophylaxis (39).
Prophylactic use of oral erythromycin or
azithromycin may promote macrolide resistance
among endemic streptococci. The Naval Medical
Center, San Diego, California, found 5(10%) of 50
consecutive clinical isolates collected during
March and April 1997 resistant to erythromycin.
While frequently reported in Europe and Japan,
macrolide resistance has been uncommon in U.S.
military populations (T. Ferguson, R. Haberberger,
pers. comm.) and infrequent in isolates from
civilians in the United States (55).
Triservice surveillance has been established
to define antibiotic resistance patterns and
determine which serotypes of S. pyogenes are
causing clinical disease (Figure 2). Data from
eight sentinel military medical treatment
facilities will be used to monitor resistance and
develop alternate prophylactic strategies, rapid
diagnostic tests, and vaccines.
Mycoplasma pneumoniae
During World War II, acute pneumonia in
military personnel was frequently milder than
lobar pneumonia. Chest radiographs showed
substantial pulmonary involvement, yet patients
did not have high fever, pleuritic chest pain, or
rigors characteristic of pneumonia caused by
S. pneumoniae. In 1943, these infections were383 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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recognized as primary atypical pneumonia,
which accounted for an estimated 68% of atypical
pneumonias among marine trainees (56) and
infected as many as 44% of recruits over a
3-month training period (57). In 1944, samples
from a patient with atypical pneumonia showed
M. pneumoniae (57,58), and soon thereafter,
M. pneumoniae was identified as an important
cause of acute respiratory disease in U.S.
military personnel (59).
A common cause of pharyngitis and
bronchopneumonia,  M. pneumoniae may also
cause fulminant pneumonia, cardiac disease,
arthritis, dermatologic conditions, and central
nervous system disease (60). Crowded military
populations are at particularly high risk for
infection. In the 1970s, up to 57% of U.S. recruits
had evidence of acute infection (61), and from the
1960s through the 1990s, as many as 56% of
pneumonia cases among recruits were due to
M. pneumoniae (62-64). Because culture and
diagnostic tests for M. pneumoniae are not
commonly available at military facilities,
M. pneumoniae is often not recognized, and
ineffective antibiotics are prescribed (62).
Few options are available for combating
M. pneumoniae epidemics. More than 25 years
ago, several studies suggested that preexisting
antibody titers might prevent infection (65,66),
and vaccine candidates were tested with mixed
success (64,67,68). In 1965, preventing disease
with a 10-day course of oxytetracycline (69)
(4 times a day) among close contacts was
successful but impractical. More recently,
weekly oral azithromycin (500 mg) had a 64%
protective efficacy (by serologic tests) against M.
pneumoniae in U.S. marines (33).
Reliable diagnostic tests and enhanced
surveillance efforts are needed to assess the
epidemiology and impact of M. pneumoniae on
military populations. With the exception of
serologic tests, few rapid diagnostic tests are
commercially available.
Bordetella pertussis
Before vaccines were available, B. pertussis
caused considerable illness in children. With the
effectiveness of whole-cell childhood vaccines,
disease incidence increased among older chil-
dren and adults, whose childhood vaccine
immunity had waned (70-74). B. pertussis
infection in adults, while generally mild (75), can
be incapacitating. No pertussis vaccines are
available for adults.
B. pertussis also affects military populations;
a 1989 study of marine trainees who reported 7
or more days of cough showed that 18% had acute
B. pertussis infection (73). The potential for
military epidemics of B. pertussis is demon-
strated by outbreaks among other confined
populations, such as those receiving general or
institutionalized medical care, which have
attack rates as high as 91% (76,77). Infection in
adults is often difficult to verify since culture and
polymerase chain reaction diagnostic tests may
be negative (73). While often used epidemiologi-
cally, serologic methods are not standardized,
nor are they routinely performed by clinical
laboratories (78). Hence, many epidemics are
monitored by clinical case definitions.
Some clinicians have observed a prophylactic
benefit in administering oral erythromycin to
close contacts of patients (78). However,
erythromycin prophylaxis is not without side
effects, and its value has been questioned (76,79).
New acellular pertussis vaccines, now approved
only for use among infants and children, are
being studied for use in adults (80).
Research and Disease Control
Trainees entering military service receive
influenza vaccine and adenovirus types 4 and 7
vaccines when available. Mass antibiotic
chemoprophylaxis is also often used to prevent
acute respiratory disease and control epidemics,
particularly those caused by S. pyogenes
infections. After initial training, military
personnel receive annual influenza vaccine and
periodic tuberculosis screening (Table).
Almost all respiratory illnesses, including
pneumonia, are treated empirically (4,62), often
with penicillin or a macrolide (62). Without
accurate laboratory diagnoses and an early
warning system to detect changes in acute
respiratory disease rates and antibiotic resis-
tance, more respiratory disease epidemics are
likely to occur in military populations. A Global
Emerging Infections Surveillance and Response
System has been established to address this
problem. Surveillance data will be used to direct
acute respiratory disease research, training, and
education. Under the system, DoD has recently
established modest surveillance programs for
influenza, adenovirus, S. pyogenes, and384 Emerging Infectious Diseases Vol. 5, No. 3, MayJune 1999
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Table. Current capacity to control respiratory pathogens at most military medical treatment facilities, United States
Rapid
Pathogen Culture diagnostic tests Prophylaxis Vaccinea
Streptococcus Available Antigen detection Benzathine penicillin G (5), Needed
  pyogenes   available and used   erythromycin (45), or
  azithromycin (33)
Streptococcus Available but Needed Azithromycin (33) Available but
   pneumoniae   not sensitive   seldom used
  among  military
  personnel
Mycoplasma Not available Serologic tests Azithromycin (33) Needed
  pneumoniae   are available
Influenza Not availableb Needed Amantadine Vaccine available
  and routinely used
Adenovirus Not availableb Needed Not available Types 4 and 7
  vaccines effective
  but not available
Bordetella Available but Needed Erythromycin prophylaxis Needed
  pertussis   not sensitive   is of questionable value (79)
aWhile a number of civilian populations, such as the institutionalized, may have similar needs these vaccine needs are
particularly urgent for crowded military trainees.
bSome medical treatment facilities have access to culture support.
S. pneumoniae at a number of U.S. military
recruit training camps and special facilities, in
collaboration with other federal, state, and
civilian organizations. Recruit sites were chosen
for their long history of respiratory disease
epidemics and the possibility of monitoring the
impact of mass antibiotic prophylaxis. Tertiary
referral medical centers were chosen to
participate because they were more likely to
detect unusual and antibiotic-resistant strains of
respiratory pathogens. Limited samples of
clinical influenza A, adenovirus, S. pyogenes,
and S. pneumoniae isolates are being studied.
However, new diagnostic tools and vaccines are
still needed (Table).
Conclusions
Military personnel, because of crowding and
unique stressors, are subject to respiratory
disease epidemics. Their risk often exceeds that
of their civilian peers. Adenovirus, influenza
virus,  S. pyogenes, S. pneumoniae, and
B. pertussis are particularly problematic.
Pathogen control measures, many of which were
developed more than 20 years ago, are
threatened by loss of vaccine production,
changes in pathogen virulence, changes in
pathogen antibiotic sensitivity, changes in
population immunity, and lack of laboratory
infrastructure to identify respiratory disease
pathogens and evaluate new diagnostic and
control measures.
Strong, laboratory-based surveillance pro-
grams are needed to quickly identify new
problems. The surveillance programs must be
supported by fast, accurate diagnostic laboratory
tests. Surveillance data must then be used to
direct the development and evaluation of new
interventions, particularly vaccines.
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